Wall Street analysts expect ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) to announce earnings per share (EPS) of ($0.34) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for ASLAN PHARMACEUTICALS ADR REP 5’s earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.36). The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that ASLAN PHARMACEUTICALS ADR REP 5 will report full-year earnings of ($1.34) per share for the current fiscal year, with EPS estimates ranging from ($1.42) to ($1.30). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.48) per share, with EPS estimates ranging from ($1.81) to ($1.09). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for ASLAN PHARMACEUTICALS ADR REP 5.
ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) last issued its quarterly earnings data on Monday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.06).
A number of hedge funds have recently added to or reduced their stakes in ASLN. MYDA Advisors LLC acquired a new position in shares of ASLAN PHARMACEUTICALS ADR REP 5 in the 2nd quarter valued at $195,000. Platinum Investment Management Ltd. purchased a new stake in ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter worth $2,532,000. Finally, Temasek Holdings Private Ltd purchased a new stake in ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter worth $12,660,000. 10.93% of the stock is owned by hedge funds and other institutional investors.
ASLN stock traded up $0.01 during midday trading on Monday, hitting $7.31. The stock had a trading volume of 513 shares, compared to its average volume of 3,677. ASLAN PHARMACEUTICALS ADR REP 5 has a 12-month low of $5.08 and a 12-month high of $10.44.
ASLAN PHARMACEUTICALS ADR REP 5 Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais (RON) inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors.
Read More: Understanding Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.